Home > Insider Trading > Filing (0001651308-21-000255)

Filing Details

Accession Number:: 0001651308-21-000255
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-16 17:50:15
Reporting Period:: 2021-12-14

Accepted Time:: 2021-12-16 17:50:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1651308	Beigene Ltd.	BGNE	Pharmaceutical Preparations (2834)	981209416

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1683913	Jane Huang	C/O Mourant Governance Services (Cayman) 94 Solaris Avenue Camana Bay, Grand Cayman E9 KY1-1108	Cmo, Hematology	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
American Depositary Shares	Acquisiton	2021-12-14	1,500	$119.96	1,500	No	4	M	Direct
American Depositary Shares	Disposition	2021-12-14	300	$274.54	1,200	No	4	S	Direct
American Depositary Shares	Disposition	2021-12-14	300	$276.95	900	No	4	S	Direct
American Depositary Shares	Disposition	2021-12-14	500	$278.21	400	No	4	S	Direct
American Depositary Shares	Disposition	2021-12-14	100	$278.79	300	No	4	S	Direct
American Depositary Shares	Disposition	2021-12-14	200	$281.64	100	No	4	S	Direct
American Depositary Shares	Disposition	2021-12-14	100	$284.52	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Share Option (Right to Buy)	Disposition	2021-12-14	19,500	$0.00	19,500	$9.23

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
211,276		2029-06-04	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Ordinary Shares	160,055	Direct

Footnotes

Each American Depositary Share represents 13 Ordinary Shares.
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.27 to $274.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.57 to $277.37, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.78 to $278.67, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.49 to $281.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
The number of securities underlying the option and the exercise price therefor are represented in ordinary shares.
These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.